Inpharzam Ricerche

Inpharzam Ricerche was a Swiss-based pharmaceutical research organization and a subsidiary of the Zambon Group. The company was primarily focused on the discovery and development of treatments for central nervous system disorders, most notably Parkinson's disease. Its most significant contribution to the field was the development of safinamide, a multi-mechanism small molecule that acts as a selective and reversible MAO-B inhibitor and a dopamine reuptake inhibitor. Following the successful development and licensing of its core assets, the entity's operations were largely integrated into the parent Zambon Group or transitioned through strategic partnerships with companies like Newron Pharmaceuticals.